MedTrace Logo

Efficacy of Aspirin in Preventing Venous Thromboembolism

NCT06635317 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-10-10

No results posted yet for this study

Summary

Efficacy of aspirin and enoxaparin in preventing venous tromboembolism was compared after total knee or hip arthroplasty.

Conditions

  • Venous Thromboembolism (VTE)
  • Total Joint Arthroplasty
  • Total Hip Arthroplasty (THA)

Interventions

DRUG

Aspirin

100 mg/day orally for 25 days

DRUG

enoxaparin

40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².

Sponsors & Collaborators

  • Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-24
Primary Completion
2022-10-24
Completion
2023-02-28
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06635317 on ClinicalTrials.gov